<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626613</url>
  </required_header>
  <id_info>
    <org_study_id>REM-TWN-MA5</org_study_id>
    <nct_id>NCT00626613</nct_id>
  </id_info>
  <brief_title>The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)</brief_title>
  <official_title>Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinan Mental Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinan Mental Hospital</source>
  <brief_summary>
    <textblock>
      To evaluate the relationship between Risperidone Treatment, Treatment Discontinuation Rate,
      and Quality of Life of patients with Alzheimer's Disease and BPSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, placebo-controlled, double blind, prospective study. The total
      duration of this study will be 12 weeks. (1). Baseline Phase: Subjects diagnosed as
      Alzheimer's Disease and BPSD will be evaluated for entry to the trial. Subjects must meet the
      inclusion/exclusion criteria before entering the treatment phase. After obtaining informed
      consent, a physical examination, brief neurologic examination, and clinical laboratory tests
      appropriate are recommended. (2). Treatment Phase: All patients enrolled will be randomized
      to treatment with Risperdal Oral Solution or Placebo. The dosage of treatment medication will
      begin with 0.5 ml/ per day (0.5mg) (as the local product information leaflet). Investigators
      can titrate dosage according to patients' clinical situation. The maximum dose will be 2ml/
      per day. The standardized assessments include NPI, which covers 12 domains of behavioral and
      neuro-vegetative symptoms, CASI for cognitive function test, and SF-36 for Quality of Life.
      Adverse events will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neoropsychiatric Inventory (NPI)Cognitive Abilities Screening Instrument (CASI) SF-36abnormal involuntary movement scale (AIMS), Barnes akathisia rating scale (BARS), and Simpson angus scale (SAS)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <condition>Dementia</condition>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperdal,reminyl</intervention_name>
    <description>Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients whose age 60 years or older diagnosed with Alzheimer's disease
             and BPSD without exposure to any antipsychotics within 1 month prior to study start.

          2. Subjects and subjects' relatives or legal representatives have signed the informed
             consent form, in accordance with the regulations of the local ethical committee.

          3. Subjects must remain in good health, as determined by medical history, complete
             physical examinations, laboratory tests and ECG.

        Exclusion Criteria:

          1. Neurodegenerative disorders such as Parkinson's disease, Pick's disease or
             Huntington's chorea, Down's syndrome, Creutzfeldt-Jacob disease.

          2. One of the following conditions possibly resulting in cognitive impairment:

             Acute cerebral trauma caused by post traumatic brain injury, subdural hematoma and
             injuries secondary to chronic trauma; hypoxic cerebral damage;; cerebral neoplasia;;
             mental retardation or oligophrenia

          3. Multi-infarct dementia or clinically active cerebrovascular disease

          4. Subjects with the severe co-existing medical conditions.

          5. Current clinically significant cardiovascular disease that would be expected to limit
             the subject's ability to participate in and complete a 3-month trial.

          6. History of drug or alcohol abuse within the last year.

          7. Female subjects of childbearing potential without adequate contraception.

          8. History of severe drug allergy or hypersensitivity; including recorded
             hypersensitivity to Risperidone.

          9. Participation in a clinical trial of any investigational drug within 1 month (30 days)
             prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ouyang Wen-Chen, Doctor of Public Health</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taiwanese Society of Psychiatry,Boarding member;Zeelandia Dementia Boarding member;Boarding member, Taiwanese Association of Geriatric Psychiatry ;Taiwan Dementia Society Boarding member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry Jinan Mental Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>717</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.cnpc.gov.tw</url>
  </link>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>February 29, 2008</last_update_submitted>
  <last_update_submitted_qc>February 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

